TY - JOUR
T1 - Patent foramen ovale and stroke
T2 - Should PFOs be closed in otherwise cryptogenic stroke
AU - Carpenter, David A.
AU - Ford, Andria L.
AU - Lee, Jin Moo
N1 - Funding Information:
Disclosure Dr. Jin-Moo Lee has received grant support from National Institutes of Health P50 NS055977, P01 NS032636, R01 NS048283, and R01 NS067905, and has been a site principal investigator for the following clinical trials: RESPECT, APCAST, SWISS, and IRIS. No other potential conflicts of interest relevant to this article were reported.
PY - 2010/7
Y1 - 2010/7
N2 - Since initial reports of its association with ischemic stroke appeared in 1988, there has been continued controversy regarding the existence and strength of the association between patent foramen ovale (PFO) and ischemic stroke. Many case-control studies have reported an association between incident cryptogenic ischemic stroke and PFO, yet population-based studies have failed to confirm this association. Studies of the risk of recurrent stroke in patients with cryptogenic stroke with or without PFO have not shown an increased risk of recurrent stroke in patients with PFO. Meanwhile, use of devices to close PFOs and atrial septal defects percutaneously has increased dramatically since their introduction. Completion of the randomized clinical trials of PFO closure currently in progress is vital to determine if the benefits of PFO closure in cryptogenic stroke outweigh its risks.
AB - Since initial reports of its association with ischemic stroke appeared in 1988, there has been continued controversy regarding the existence and strength of the association between patent foramen ovale (PFO) and ischemic stroke. Many case-control studies have reported an association between incident cryptogenic ischemic stroke and PFO, yet population-based studies have failed to confirm this association. Studies of the risk of recurrent stroke in patients with cryptogenic stroke with or without PFO have not shown an increased risk of recurrent stroke in patients with PFO. Meanwhile, use of devices to close PFOs and atrial septal defects percutaneously has increased dramatically since their introduction. Completion of the randomized clinical trials of PFO closure currently in progress is vital to determine if the benefits of PFO closure in cryptogenic stroke outweigh its risks.
KW - Atrial septal aneurysm
KW - Cerebral infarction
KW - Cryptogenic stroke
KW - Hypercoagulable state
KW - Paradoxical embolism
KW - Patent foramen ovale
KW - Patent foramen ovale closure
KW - Stroke
UR - http://www.scopus.com/inward/record.url?scp=77955978449&partnerID=8YFLogxK
U2 - 10.1007/s11883-010-0114-7
DO - 10.1007/s11883-010-0114-7
M3 - Review article
C2 - 20461560
AN - SCOPUS:77955978449
SN - 1523-3804
VL - 12
SP - 251
EP - 258
JO - Current atherosclerosis reports
JF - Current atherosclerosis reports
IS - 4
ER -